Role of Body Composition in Patients with Resectable Pancreatic Cancer

Overview

Journal Nutrients

Date 2024 Jun 27

PMID 38931189

Authors

Annarita Pecchi

Filippo Valoriani

Riccardo Cuoghi Costantini

Denise Squecco

Andrea Spallanzani

Roberto DAmico

Massimo Dominici

Fabrizio Di Benedetto

Pietro Torricelli

Renata Menozzi

Affiliations

Soon will be listed here.

Abstract

This study investigates the role of body composition parameters in patients with pancreatic cancer undergoing surgical treatment. The research involved 88 patients diagnosed with pancreatic cancer who underwent surgery at the Modena Cancer Center between June 2015 and October 2023. Body composition parameters were obtained from CT scans performed before and after surgery. The percentage of sarcopenic patients at the time of diagnosis of pancreatic cancer is 56.82%. Of the patients who died between the first and second CT evaluated, 58% were sarcopenic, thus confirming the role of sarcopenia on outcome. The study found that all body composition parameters (TAMA, SMI, VFI, and SFI) demonstrated a trend towards reduction between two examinations, indicating an overall depletion in muscle and adipose tissue. We then evaluated the relationships between fat-related parameters (VFI, SFI and VSR) and survival outcomes: overall survival and progression-free survival. Cox univariate regression model show significant parameter related to outcomes was adipose tissue, specifically VFI. The study found that higher VFI levels were associated with greater survival rates. This research holds promise for advancing our understanding of the link between body composition and the prognosis of pancreatic cancer patients.

References

Saif M . Advancements in the management of pancreatic cancer: 2013. JOP. 2013; 14(2):112-8. DOI: 10.6092/1590-8577/1481. View

Tagliafico A, Bignotti B, Torri L, Rossi F . Sarcopenia: how to measure, when and why. Radiol Med. 2022; 127(3):228-237. PMC: 8960583. DOI: 10.1007/s11547-022-01450-3. View

Ninomiya G, Fujii T, Yamada S, Yabusaki N, Suzuki K, Iwata N . Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. Int J Surg. 2017; 39:45-51. DOI: 10.1016/j.ijsu.2017.01.075. View

Fielding R, Vellas B, Evans W, Bhasin S, Morley J, Newman A . Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011; 12(4):249-56. PMC: 3377163. DOI: 10.1016/j.jamda.2011.01.003. View

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

Menozzi R, Valoriani F, Ballarin R, Alemanno L, Vinciguerra M, Barbieri R . Impact of Nutritional Status on Postoperative Outcomes in Cancer Patients following Elective Pancreatic Surgery. Nutrients. 2023; 15(8). PMC: 10141114. DOI: 10.3390/nu15081958. View

Tan B, Birdsell L, Martin L, Baracos V, Fearon K . Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009; 15(22):6973-9. DOI: 10.1158/1078-0432.CCR-09-1525. View

Carrara G, Pecorelli N, De Cobelli F, Cristel G, Damascelli A, Beretta L . Preoperative sarcopenia determinants in pancreatic cancer patients. Clin Nutr. 2016; 36(6):1649-1653. DOI: 10.1016/j.clnu.2016.10.014. View

Cruz-Jentoft A, Gonzalez M, Prado C . Sarcopenia ≠ low muscle mass. Eur Geriatr Med. 2023; 14(2):225-228. DOI: 10.1007/s41999-023-00760-7. View

10.

Albano D, Messina C, Vitale J, Sconfienza L . Imaging of sarcopenia: old evidence and new insights. Eur Radiol. 2019; 30(4):2199-2208. DOI: 10.1007/s00330-019-06573-2. View

11.

Bian X, Dai H, Feng J, Ji H, Fang Y, Jiang N . Prognostic values of abdominal body compositions on survival in advanced pancreatic cancer. Medicine (Baltimore). 2018; 97(22):e10988. PMC: 6393092. DOI: 10.1097/MD.0000000000010988. View

12.

Pecorelli N, Carrara G, De Cobelli F, Cristel G, Damascelli A, Balzano G . Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Br J Surg. 2016; 103(4):434-42. DOI: 10.1002/bjs.10063. View

13.

Guarneri G, Pecorelli N, Bettinelli A, Campisi A, Palumbo D, Genova L . Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer. Eur J Surg Oncol. 2023; 50(5):106848. DOI: 10.1016/j.ejso.2023.02.005. View

14.

Williams T, Rosato E, Kennedy E, Chojnacki K, Andrel J, Hyslop T . Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy. J Am Coll Surg. 2009; 208(2):210-7. DOI: 10.1016/j.jamcollsurg.2008.10.019. View

15.

Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C . Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage. 2012; 44(2):181-91. PMC: 3990439. DOI: 10.1016/j.jpainsymman.2011.09.010. View

16.

Mourtzakis M, Prado C, Lieffers J, Reiman T, McCargar L, Baracos V . A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997-1006. DOI: 10.1139/H08-075. View

17.

Liu C, An L, Zhang S, Deng S, Wang N, Tang H . Association between preoperative sarcopenia and prognosis of pancreatic cancer after curative-intent surgery: a updated systematic review and meta-analysis. World J Surg Oncol. 2024; 22(1):38. PMC: 10825983. DOI: 10.1186/s12957-024-03310-y. View

18.

Paiella S, Azzolina D, Trestini I, Malleo G, Nappo G, Ricci C . Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis. Front Nutr. 2023; 10:1065294. PMC: 9968808. DOI: 10.3389/fnut.2023.1065294. View

19.

Latenstein A, Dijksterhuis W, Mackay T, Beijer S, van Eijck C, de Hingh I . Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study. Cancer Med. 2020; 9(24):9385-9395. PMC: 7774726. DOI: 10.1002/cam4.3556. View

20.

Chan M, Chok K . Sarcopenia in pancreatic cancer - effects on surgical outcomes and chemotherapy. World J Gastrointest Oncol. 2019; 11(7):527-537. PMC: 6657219. DOI: 10.4251/wjgo.v11.i7.527. View